A novel regulation of VEGF expression by HIF-1α and STAT3 in HDM2 transfected prostate cancer cells

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 8, 2012, Pages 1750-1757

  Rathinavelu, Appu ^a,b   Narasimhan, Madhusudhanan ^c   Muthumani, Praneetha ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Angiogenesis; HDM2; HIF 1 ; Hypoxia; STAT3; VEGF

Indexed keywords

HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MDM2 PROTEIN, HUMAN; PROTEIN MDM2; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; CELL HYPOXIA; CELL PROLIFERATION; CELL SHAPE; GENETIC TRANSFECTION; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84864389212     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01472.x     Document Type: Article

References (40)

1. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003; 3: 102-9.
2. Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 2005; 5: 27-41.
3. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004; 2: 1-8.
4. Jones SN, Hancock AR, Vogel H, et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998; 95: 15608-12.
5. Alkhalaf M, Ganguli G, Messaddeq N, et al. MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. Oncogene. 1999; 18: 1419-34.
6. Ganguli G, Abecassis J, Wasylyk B. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis. EMBO J. 2000; 19: 5135-47.
7. Rathinavelu P, Malave A, Raney SR, et al. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumour (GI-101) implanted athymic nude mice. Cancer Biochem Biophys. 1999; 17: 133-46.
8. Folkman J. Role of angiogenesis in tumour growth and metastasis. Semin Oncol. 2002; 29: 15-8.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-57.
10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18: 4-25.
11. Ansó E, Zuazo A, Irigoyen M, et al. Flavonoids inhibit hypoxia-induced vascular endothelial growth factor expression by a HIF-1 independent mechanism. Biochem Pharmacol. 2010; 79: 1600-9.
12. Gray MJ, Zhang J, Ellis LM, et al. HIF-1[alpha], STAT3, CBP//p300 and Ref-1//APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005; 24: 3110-20.
13. Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002; 161: 2295-309.
14. Ramakrishnan R, Zell JA, Malav A, et al. Expression of vascular endothelial growth factor mRNA in GI-101A and HL-60 cell lines. Biochem Biophys Res Commun. 2000; 270: 709-13.
15. Narasimhan M, Rose R, Karthikeyan M, et al. Detection of HDM2 and VEGF co-expression in cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression. Life Sci. 2007; 81: 1362-72.
16. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumour angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 2000; 14: 34-44.
17. Wang GL, Jiang BH, Rue EA, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92: 5510-4.
18. Huang LE, Gu J, Schau M, et al. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998; 95: 7987-92.
19. Wu L, Levine AJ. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol Med. 1997; 3: 441-51.
20. Zhong H, Agani F, Baccala AA, et al. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998; 58: 5280-4.
21. Akakura N, Kobayashi M, Horiuchi I, et al. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001; 61: 6548-54.
22. Tacchini L, De Ponti C, Matteucci E, et al. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis. 2004; 25: 2089-100.
23. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5: 343-54.
24. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002; 295: 858-61.
25. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15: 2675-86.
26. Lee YM, Lim JH, Chun YS, et al. Nutlin-3, an Hdm2 antagonist, inhibits tumour adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis. 2009; 30: 1768-75.
27. Lee H-Y, Lee T, Lee N, et al. Src activates HIF-1α not through direct phosphorylation of HIF-1α-specific prolyl-4 hydroxylase 2 but through activation of the NADPH oxidase/Rac pathway. Carcinogenesis. 2011; 32: 703-12.
28. Chun YS, Lee KH, Choi E, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumour promotion. Cancer Res. 2003; 63: 8700-7.
29. Katschinski DM, Le L, Heinrich D, et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on heat shock protein-90 activity. J Biol Chem. 2002; 277: 9262-7.
30. Wenger RH, Rolfs A, Spielmann P, et al. Mouse hypoxia-inducible factor-1alpha is encoded by two different mRNA isoforms: expression from a tissue-specific and a housekeeping-type promoter. Blood. 1998; 91: 3471-80.
31. Marechal V, Elenbaas B, Piette J, et al. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol. 1994; 14: 7414-20.
32. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene. 2000; 19: 2474-88.
33. Huang M, Page C, Reynolds RK, et al. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000; 79: 67-73.
34. Ni Z, Lou W, Leman ES, et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000; 60: 1225-8.
35. Badoux X, Bueso-Ramos C, Harris D, et al. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011. doi: 10.1016/j.humpath.2011.02.027.
36. Mukhopadhyay D, Tsiokas L, Zhou XM, et al. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 1995; 375: 577-81.
37. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumour cell growth. Oncogene. 2002; 21: 7001-10.
38. Zhang Q, Nowak I, Vonderheid EC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci U S A. 1996; 93: 9148-53.
39. Lin J, Tang H, Jin X, et al. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene. 2002; 21: 3082-8.
40. Koh MY, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci. 2008; 33: 526-34.